
## **Biagio Pinchera**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6551847/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	1.1	137
2	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	1.8	87
3	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?. Frontiers in Cellular and Infection Microbiology, 2021, 11, 625581.	1.8	59
4	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. Life Sciences, 2020, 261, 118355.	2.0	32
5	Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. Reviews on Recent Clinical Trials, 2019, 14, 173-182.	0.4	30
6	Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. International Journal of Infectious Diseases, 2017, 63, 23-29.	1.5	26
7	Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. International Journal of Environmental Research and Public Health, 2021, 18, 2078.	1.2	24
8	Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. International Journal of Environmental Research and Public Health, 2021, 18, 11399.	1.2	24
9	Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. Internal and Emergency Medicine, 2020, 15, 263-271.	1.0	23
10	<i>Pneumocystis jirovecii</i> pneumonia in an immunocompetent patient recovered from COVID-19. Infectious Diseases, 2021, 53, 382-385.	1.4	23
11	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. Journal of Nephrology, 2019, 32, 763-773.	0.9	21
12	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Frontiers in Medicine, 2021, 8, 639970.	1.2	20
13	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs, 2016, 25, 557-572.	1.9	19
14	Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?. Frontiers in Public Health, 2021, 9, 664108.	1.3	19
15	Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiologica, 2018, 41, 26-29.	0.1	18
16	Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience. Transplantation, 2022, 106, e343-e345.	0.5	17
17	Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. Sexual Health, 2018, 15, 408.	0.4	16
18	Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. In Vivo, 2019, 33, 177-182.	0.6	16

**BIAGIO PINCHERA** 

#	Article	IF	CITATIONS
19	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients. Journal of Clinical Medicine, 2021, 10, 4914.	1.0	14
20	A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study. Viruses, 2021, 13, 1718.	1.5	13
21	B-Type Natriuretic Peptides and High-Sensitive Troponin I as COVID-19 Survival Factors: Which One Is the Best Performer?. Journal of Clinical Medicine, 2021, 10, 2726.	1.0	11
22	Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?. Viruses, 2022, 14, 534.	1.5	10
23	Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. Expert Opinion on Pharmacotherapy, 2018, 19, 1317-1325.	0.9	9
24	Low vitamin D levels are associated with the presence of serum cryoglobulins in patients with chronic HCV infection. In Vivo, 2015, 29, 399-404.	0.6	9
25	Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opinion on Pharmacotherapy, 2020, 21, 261-273.	0.9	8
26	Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19. Minerva Endocrinology, 2022, 47, .	0.6	8
27	SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience. Frontiers in Medicine, 2022, 9, 864865.	1.2	8
28	Further Findings Concerning Endothelial Damage in COVID-19 Patients. Biomolecules, 2021, 11, 1368.	1.8	7
29	The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e57-e60.	0.7	6
30	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. Medicine (United States), 2020, 99, e18948.	0.4	6
31	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. Reviews on Recent Clinical Trials, 2019, 14, 129-135.	0.4	6
32	Current evidence on the management of hepatitis B in pregnancy. World Journal of Hepatology, 2018, 10, 585-594.	0.8	5
33	Gastrointestinal tract diseases as a risk factor for SARSCoV2 rectal shedding? An Italian report on 10 COVID-19 patients. Intestinal Research, 2021, 19, 354-356.	1.0	5
34	Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. New Microbiologica, 2019, 42, 94-100.	0.1	5
35	Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study. Infezioni in Medicina, 2019, 27, 32-39.	0.7	4
36	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Review of Anti-Infective Therapy, 2020, 18, 191-202.	2.0	3

**BIAGIO PINCHERA** 

#	Article	IF	CITATIONS
37	No Detection of SARS-CoV-2 RNA on Urethral Swab in Patients with Positive Nasopharyngeal Swab. Advances in Virology, 2020, 2020, 1-4.	0.5	3
38	Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients. Clinical Epidemiology and Global Health, 2022, 16, 101100.	0.9	3
39	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103814.	0.9	2
40	Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders. In Vivo, 2018, 32, 1255-1258.	0.6	1
41	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life â€~Llver Network Activity' (LINA) cohort update results. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1057-1063.	1.4	1
42	Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma. Frontiers in Oncology, 2021, 11, 705948.	1.3	1
43	Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience. Reviews on Recent Clinical Trials, 2022, 17, .	0.4	1